The regenerative medicines market, cumulative of tissue engineering products, gene therapy, and stem cell therapy is fragmented in nature due to the involvement of numerous global as well as regional players in this industry. According to BIS Helathcare market intelligence report titled ‘Global Regenerative Medicines Market – Analysis and Forecast (2017-2025)’, most of the companies in this sector are in clinical stage and are expected to launch their products in the coming few years. The global regenerative medicines market is generally dominated by the global orthopedic and wound biologics companies, however, depending on the geographical areas the market of these players varies accordingly. Efficient distribution networks, product differentiation, and supply competency play a major role in determining the market position of such players. Majority of these players are focusing on expanding distribution network as well as expanding presence, as the Asia Pacific, Latin America and the Middle East are the developing regions and there is an increasing awareness about tissue and cell-based products.
Recently in February 2018, one of the key market players, Acelity LP Inc., sold its regenerative medicine company, LifeCell Corp., to Allergan for $2.9 billion. Company President and CEO Joe Woody said, “This milestone is an important step in the continued evolution of Acelity. We now look ahead to fully dedicating our resources to building and strengthening our leadership in advanced wound therapies across the globe.” Allergan has now secured an opportunity to use its acquisition of LifeCell as an entry point into regenerative medicine.1
In January 2018, Cellular Biomedicine Group Inc (CBMG) announced that it has GE Healthcare’s FlexFactory technology for its CAR-T therapy production facility in Shanghai, China. According to CBMG, this move will help them to accelerate and improve the production of their portfolio of Chimeric Antigen Receptor (CAR) T-Cell therapies.2 Prior to this development in the market, Mesoblast Ltd. announced in a press release, in Dec 2107, that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its novel mesenchymal precursor cell (MPC) therapy in the treatment of heart failure patients with left ventricular systolic dysfunction and left ventricular assist devices (LVADs). The RMAT designation under the 21st Century Cures Act aims to expedite the development of regenerative medicine therapies intended for the treatment of serious diseases and life-threatening conditions.
The acceleration in the research and development of regenerative medicines in the healthcare industry has compelled BIS Research to compile a market intelligence report which gives an insight to gain a holistic view of the regenerative medicine market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. According to the analyst, “the global regenerative medicines market generated $17.03 billion revenue in 2016 and is expected to reach $50.55 billion by 2025. The rapid expansion of the stem cell and gene therapy in the developed markets such as the U.S., Japan, Germany, and the U.K. is the key driver for the growth of regenerative medicines market.”
1 San Antonio Business Journal
2 BioPharma Reporter